Zoetis said it will guide conservatively for 2027 as pet owners scale back discretionary vet visits, pressuring near-term revenue prospects. The muted outlook followed a period of robust growth and shares fell on the news, highlighting investor concerns about demand elasticity in routine veterinary services. The key question is whether demand improves into 2027 or remains restrained.
Zoetis topped Q3 expectations with EPS of $1.75 on $2.391B revenue, beating estimates. U.S. Companion Animal weakness offset by Livestock and Diagnostics growth. The company raised its 2026 adjusted EPS to $6.25-$6.35 and 2026 sales to $9.22B-$9.32B, signaling confidence despite ongoing vet-visit and price-headwinds. Shares fell about 6% on the results, with longer-term upside tied to 2027-2028 launches.
The FDA granted emergency use authorization for Zoetis' flea and tick product to combat New World screwworm infestations in dogs and puppies. This regulatory endorsement could unlock short-term demand for Zoetis' veterinary portfolio and may lift sentiment around ZTS, particularly within pet-health offerings. The impact will depend on patient access, supply, and broader adoption.
Zoetis reported a Q2 revenue miss and cut its full-year forecast as softer demand for pet healthcare products and heightened competition weigh on the business. The revision signals near-term earnings pressure and potential multiple re-rating if visibility on pricing and cost controls remains weak, making near-term risk-off sentiment likely for ZTS holders.
Zoetis reported weaker than expected earnings and sales, prompting a revision of its fiscal 2026 guidance downwards. The missed consensus highlights ongoing challenges in the U.S. market, especially in pet care, which may weigh on stock performance in the near-term.
Zoetis achieved strong Q4 2025 results with $2.4 billion in revenue and adjusted EPS of $1.48, surpassing expectations. The company’s optimistic 2026 forecast, backed by robust demand in the companion-animal sector, is likely to sustain its stock momentum.